Telomerase Antagonists GRN163 and GRN163L Inhibit Tumor Growth and Increase Chemosensitivity of Human Hepatoma *

Telomeres shorten during ageing of human fibroblasts

Harley, C. B., Futcher, A. B., & Greider, C. W. (1990) · Nature · doi:10.1038/345458a0 · Cited by 5,750 · see citing works

Hepatocellular carcinoma

Llovet, J. M., Burroughs, A. K., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,613 · see citing works

Identification of a specific telomere terminal transferase activity in tetrahymena extracts

Greider, C. W., & Blackburn, E. H. (1985) · Cell · doi:10.1016/0092-8674(85)90170-9 · Cited by 3,400 · see citing works

A DNA damage checkpoint response in telomere-initiated senescence

Fagagna, F. D. D., Reaper, P. M., Clay-Farrace, L., Fiegler, H., Carr, P., von Zglinicki, T., Saretzki, G., Carter, N. P., & Jackson, S. P. (2003) · Nature · doi:10.1038/nature02118 · Cited by 2,855 · see citing works

A survey of telomerase activity in human cancer

Shay, J. W., & Bacchetti, S. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00062-2 · Cited by 2,794 · see citing works

Megabase Chromatin Domains Involved in DNA Double-Strand Breaks in Vivo

Rogakou, E. P., Boon, C., Redon, C., & Bonner, W. M. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.5.905 · Cited by 2,422 · see citing works

Telomere length predicts replicative capacity of human fibroblasts.

Allsopp, R. C., Vaziri, H., Patterson, C., Goldstein, S., Younglai, E. V., Futcher, A. B., Greider, C. W., & Harley, C. B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.21.10114 · Cited by 2,200 · see citing works

Human Hepatocellular Carcinoma Cell Lines Secrete the Major Plasma Proteins and Hepatitis B Surface Antigen

Knowles, B. B., Howe, C. C., & Aden, D. P. (1980) · Science · doi:10.1126/science.6248960 · Cited by 2,026 · see citing works

p53 Deficiency Rescues the Adverse Effects of Telomere Loss and Cooperates with Telomere Dysfunction to Accelerate Carcinogenesis

Chin, L., Artandi, S. E., Shen, Q., Tam, A., Lee, S.-L., Gottlieb, G. J., Greider, C. W., & DePinho, R. A. (1999) · Cell · doi:10.1016/s0092-8674(00)80762-x · Cited by 979 · see citing works

Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes.

Vaziri, H., Schächter, F., Uchida, I. A., Wei, L., Zhu, X., Effros, R. B., Cohen, D., & Harley, C. (1993) · PubMed · Cited by 734 · see citing works

Telomere dysfunction and evolution of intestinal carcinoma in mice and humans

Rudolph, K. L., Millard, M., Bosenberg, M. W., & DePinho, R. A. (2001) · Nature Genetics · doi:10.1038/88871 · Cited by 527 · see citing works

Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis

WIEMANN, S. U., SATYANARAYANA, A., TSAHURIDU, M., TILLMANN, H. L., ZENDER, L., KLEMPNAUER, J., FLEMMING, P., FRANCO, S., BLASCO, M. A., MANNS, M. P., et al. (2002) · The FASEB Journal · doi:10.1096/fj.01-0977com · Cited by 527 · see citing works

Tumor Suppressor P53 Binding Protein 1 (53bp1) Is Involved in DNA Damage–Signaling Pathways

Rappold, I., Iwabuchi, K., Date, T., & Chen, J. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.153.3.613 · Cited by 487 · see citing works

A highly selective telomerase inhibitor limiting human cancer cell proliferation

Damm, K., Hemmann, U., Garin‐Chesa, P., Hauel, N., Kauffmann, I., Priepke, H., Niestroj, C., Daiber, C., Enenkel, B., Guilliard, B., et al. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6958 · Cited by 422 · see citing works

The two-stage mechanism controlling cellular senescence and immortalization

Wright, W. E., & Shay, J. W. (1992) · Experimental Gerontology · doi:10.1016/0531-5565(92)90069-c · Cited by 383 · see citing works

Short Dysfunctional Telomeres Impair Tumorigenesis in the INK4aΔ2/3 Cancer-Prone Mouse

Greenberg, R. A., Chin, L., Femino, A., Lee, K.-H., Gottlieb, G. J., Singer, R. H., Greider, C. W., & DePinho, R. A. (1999) · Cell · doi:10.1016/s0092-8674(00)80761-8 · Cited by 367 · see citing works

Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis

González-Suárez, E., Samper, E., Flores, J. M., & Blasco, M. A. (2000) · Nature Genetics · doi:10.1038/79089 · Cited by 347 · see citing works

Telomerase activity in human liver tissues: comparison between chronic liver disease and hepatocellular carcinomas.

Tahara, H., Nakanishi, T., Kitamoto, M., NAKASHIO, R., Shay, J. W., Tahara, E., Kajiyama, G., & Ide, T. (1995) · PubMed · Cited by 310 · see citing works

Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation

Wong, K.-K., Chang, S., Weiler, S. R., Ganesan, S., Chaudhuri, J., Zhu, C., Artandi, S. E., Rudolph, K. L., Gottlieb, G. J., Chin, L., et al. (2000) · Nature Genetics · doi:10.1038/79232 · Cited by 309 · see citing works

Cellular senescence as a tumor-protection mechanism: the essential role of counting

Wright, W. E., & Shay, J. W. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00163-5 · Cited by 306 · see citing works

Lipid modification of GRN163, an N3′ → P5′ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition

Herbert, B., Gellert, G. C., Hochreiter, A. E., Pongracz, K., Wright, W. E., Zielińska, D., Chin, A. C., Harley, C. B., Shay, J. W., & Gryaznov, S. M. (2005) · Oncogene · doi:10.1038/sj.onc.1208760 · Cited by 269 · see citing works

A novel telomerase template antagonist (GRN163) as a potential anticancer agent.

Asai, A., Oshima, Y., Yamamoto, Y., Uochi, T., Kusaka, H., Akinaga, S., Yamashita, Y., Pongracz, K., Pruzan, R., Wunder, E., et al. (2003) · PubMed · Cited by 239 · see citing works

Telomere shortening impairs organ regeneration by inhibiting cell cycle re‐entry of a subpopulation of cells

Satyanarayana, A., Wiemann, S. U., Buer, J., Lauber, J., Dittmar, K. E. J., Wüstefeld, T., Blasco, M. A., Manns, M. P., & Rudolph, K. L. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg367 · Cited by 158 · see citing works

Telomeres and telomerase: A dual role in hepatocarcinogenesis

Ande, S., Manns, M. P., & Rudolph, K. L. (2004) · Hepatology · doi:10.1002/hep.20308 · Cited by 157 · see citing works

Hepatocellular telomere shortening correlates with chromosomal instability and the development of human hepatoma

Plentz, R. R., Caselitz, M., Bleck, J. S., Gebel, M., Flemming, P., Kubicka, S., Manns, M. P., & Rudolph, K. L. (2004) · Hepatology · doi:10.1002/hep.20271 · Cited by 130 · see citing works

Oligonucleotide N3′→P5′ phosphoramidates as efficient telomerase inhibitors

Herbert, B., Pongracz, K., Shay, J. W., & Gryaznov, S. M. (2002) · Oncogene · doi:10.1038/sj.onc.1205064 · Cited by 119 · see citing works

Human Immunodeficiency Virus and Hepatitis C Virus Coinfection: Epidemiology, Natural History, Therapeutic Options and Clinical Management

Verucchi, G., Calza, L., Manfredi, R., & Chiodo, F. (2004) · Infection · doi:10.1007/s15010-004-3063-7 · Cited by 118 · see citing works

Telomerase inhibition as cancer therapy

Saretzki, G. C. (2003) · Cancer Letters · doi:10.1016/s0304-3835(02)00708-5 · Cited by 114 · see citing works

Telomere dysfunction alters the chemotherapeutic profile of transformed cells

Lee, K.-H., Rudolph, K. L., Ju, Y.-J., Greenberg, R. A., Cannizzaro, L. A., Chin, L., Weiler, S. R., & DePinho, R. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051629198 · Cited by 110 · see citing works

Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach.

Mo, Y., Gan, Y., Song, S., Johnston, J. S., Xiao, X., Wientjes, M. G., & Au, J. L. ‐. (2003) · PubMed · Cited by 90 · see citing works

The cellular level of telomere dysfunction determines induction of senescence or apoptosis in vivo

Lechel, A., Ande, S., Ju, Z., Plentz, R. R., Schaetzlein, S., Rudolph, C., Wilkens, L., Wiemann, S. U., Saretzki, G. C., Malek, N. P., et al. (2005) · EMBO Reports · doi:10.1038/sj.embor.7400352 · Cited by 88 · see citing works

Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma

Wang, E. S., Wu, K., Chin, A. C., Chen‐Kiang, S., Pongracz, K., Gryaznov, S. M., & Moore, M. A. S. (2003) · Blood · doi:10.1182/blood-2003-02-0546 · Cited by 83 · see citing works

The use of chloromethyl-X-rosamine (Mitotracker Red) to measure loss of mitochondrial membrane potential in apoptotic cells is incompatible with cell fixation

Gilmore, K. J., & Wilson, M. R. (1999) · Cytometry · doi:10.1002/(sici)1097-0320(19990801)36:4 · Cited by 81 · see citing works

Phosphorylation of H2AX at Short Telomeres in T Cells and Fibroblasts

Hao, L.-Y., Strong, M. A., & Greider, C. W. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403924200 · Cited by 71 · see citing works

Activation of the DNA Damage Response by Telomere Attrition: A Passage to Cellular Senescence

Reaper, P. M., di Fagagna, F. D., & Jackson, S. P. (2004) · Cell Cycle · doi:10.4161/cc.3.5.835 · Cited by 62 · see citing works

Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts

Ozawa, T., Gryaznov, S. M., Hu, L. J., Pongracz, K., Santos, R. A., Bollen, A. W., Lamborn, K. R., & Deen, D. F. (2004) · Neuro-Oncology · doi:10.1215/s1152851704000055 · Cited by 56 · see citing works

Identification of a quinoxaline derivative that is a potent telomerase inhibitor leading to cellular senescence of human cancer cells

Kim, J. H., Kim, J. H., Lee, G. E., Kim, S. W., & Chung, I. K. (2003) · Biochemical Journal · doi:10.1042/bj20030363 · Cited by 54 · see citing works

Telomeres and telomerase: new targets for the treatment of liver cirrhosis and hepatocellular carcinoma

Lechel, A., Manns, M. P., & Rudolph, K. L. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.06.010 · Cited by 44 · see citing works

Inhibition of telomerase activity by a distamycin derivative: effects on cell proliferation and induction of apoptosis in human cancer cells

Zaffaroni, N., Lualdi, S., Villa, R., Bellarosa, D., Cermele, C., Felicetti, P., Rossi, C., Orlandi, L., & Daidone, M. G. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00139-9 · Cited by 39 · see citing works

In situdetection of telomerase enzymatic activity in human hepatocellular carcinogenesis

Youssef, N., Paradis, V., Ferlicot, S., & Bédossa, P. (2001) · The Journal of Pathology · doi:10.1002/path.901 · Cited by 37 · see citing works

Measurement of telomere length in haematopoietic cells using in situ hybridization techniques

Martens, U. M., Brass, V., Engelhardt, M. M., Gläser, S., Waller, C. F., Lange, W., Schmoor, C., Poon, S. S. S., & Lansdorp, P. M. (2000) · Biochemical Society Transactions · doi:10.1042/bst0280245 · Cited by 35 · see citing works

Oligonucleotide N3′ → P5′ Thio-phosphoramidate Telomerase Template Antagonists as Potential Anticancer Agents

Gryaznov, S. M., Asai, A., Oshima, Y., Yamamoto, Y., Pongracz, K., Pruzan, R., Wunder, E., Piatyszek, M. A., Li, S., Chin, A. C., et al. (2003) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1081/ncn-120021958 · Cited by 31 · see citing works

Hepatocellular carcinoma: Updates in primary prevention

Fecht, W. J., & Befeler, A. S. (2004) · Current Gastroenterology Reports · doi:10.1007/s11894-004-0024-3 · Cited by 10 · see citing works

Erratum: Oligonucleotide N3′→P5′ phosphoramidates as efficient telomerase inhibitors

Herbert, B., Pongracz, K., Shay, J. W., & Gryaznov, S. M. (2002) · Oncogene · doi:10.1038/sj.onc.1205403 · Cited by 3 · see citing works

Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis

El‐Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,401 · see citing works

Cellular Senescence: Aging, Cancer, and Injury

Calcinotto, A., Kohli, J., Zagato, E., Pellegrini, L., Demaria, M., & Alimonti, A. (2019) · Physiological Reviews · doi:10.1152/physrev.00020.2018 · Cited by 1,270 · see citing works

Diagnosis and Treatment of Hepatocellular Carcinoma

El‐Serag, H. B., Marrero, J. A., Rudolph, K. L., & Reddy, K. R. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.090 · Cited by 1,138 · see citing works

Telomerase and cancer therapeutics

Harley, C. B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2275 · Cited by 728 · see citing works

Targeting telomeres and telomerase

Cian, A. D., Lacroix, L., Douarre, C., Temime‐Smaali, N., Trentesaux, C., Riou, J., & Mergny, J. (2007) · Biochimie · doi:10.1016/j.biochi.2007.07.011 · Cited by 571 · see citing works

Telomerase therapeutics for cancer: challenges and new directions

Shay, J. W., & Wright, W. E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2081 · Cited by 434 · see citing works

Telomere dysfunction and tumour suppression: the senescence connection

Deng, Y., Chan, S. S., & Chang, S. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2393 · Cited by 411 · see citing works

New therapies for hepatocellular carcinoma

Avila, M. A., Berasain, C., Sangro, B., & Prìeto, J. (2006) · Oncogene · doi:10.1038/sj.onc.1209550 · Cited by 384 · see citing works

Hepatocellular carcinoma: signaling pathways and therapeutic advances

Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 387 · see citing works

Chemistry in human telomere biology: structure, function and targeting of telomere DNA/RNA

Xu, Y. (2011) · Chemical Society Reviews · doi:10.1039/c0cs00134a · Cited by 322 · see citing works

Novel anticancer therapeutics targeting telomerase

Ruden, M., & Puri, N. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.06.007 · Cited by 309 · see citing works

Understanding TERT Promoter Mutations: A Common Path to Immortality

Bell, R. J. A., Rube, H. T., Xavier‐Magalhães, A., Costa, B. M., Mancini, A., Song, J. S., & Costello, J. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0003 · Cited by 303 · see citing works

The role of telomeres and telomerase in cirrhosis and liver cancer

Nault, J., Ningarhari, M., Rebouissou, S., & Zucman‐Rossi, J. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0165-3 · Cited by 241 · see citing works

Oncogene-induced telomere dysfunction enforces cellular senescence in human cancer precursor lesions.

Suram, A., Kaplunov, J., Patel, P. L., Ruan, H., Cerutti, A., Boccardi, V., Fumagalli, M., Di Micco, R., Mirani, N., Gurung, R. L., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.132 · Cited by 227 · see citing works

Sirtuin 1 Is Upregulated in a Subset of Hepatocellular Carcinomas where It Is Essential for Telomere Maintenance and Tumor Cell Growth

Chen, J., Zhang, B., Wong, N., Lo, A. W. I., To, K., Chan, A. W. H., Ng, M. H. L., Ho, C. Y. S., Cheng, S.-H., Lai, P. B. S., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4274 · Cited by 188 · see citing works

Ageing, telomeres, senescence, and liver injury

Hoare, M., Das, T., & Alexander, G. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.06.009 · Cited by 182 · see citing works

Signaling pathways in hepatocellular carcinoma

García‐Lezana, T., Lopez-Canovas, J. L., & Villanueva, A. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.10.002 · Cited by 168 · see citing works

Induction of Telomere Dysfunction Mediated by the Telomerase Substrate Precursor 6-Thio-2′-Deoxyguanosine

Mender, I., Gryaznov, S. M., Dikmen, Z. G., Wright, W. E., & Shay, J. W. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0609 · Cited by 161 · see citing works

Is telomerase a viable target in cancer?

Buseman, C. M., Wright, W. E., & Shay, J. W. (2011) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2011.07.006 · Cited by 145 · see citing works

Telomerase Template Antagonist GRN163L Disrupts Telomere Maintenance, Tumor Growth, and Metastasis of Breast Cancer

Hochreiter, A. E., Xiao, H., Goldblatt, E. M., Gryaznov, S. M., Miller, K. D., Badve, S., Sledge, G. W., & Herbert, B.-S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2760 · Cited by 146 · see citing works

The Telomerase Inhibitor Imetelstat Depletes Cancer Stem Cells in Breast and Pancreatic Cancer Cell Lines

Joseph, I., Tressler, R., Bassett, E., Harley, C. B., Buseman, C. M., Pattamatta, P., Wright, W. E., Shay, J. W., & Go, N. F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0233 · Cited by 144 · see citing works

Targeting c-Myc as a novel approach for hepatocellular carcinoma

Lin, C.-P., Liu, C.-R., Lee, C.-N., Chan, T., & Liu, H. E. (2010) · World Journal of Hepatology · doi:10.4254/wjh.v2.i1.16 · Cited by 138 · see citing works

Role of telomeres and telomerase in genomic instability, senescence and cancer

Deng, Y., & Chang, S. S. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700673 · Cited by 125 · see citing works

Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target

Ningarhari, M., Caruso, S., Hirsch, T. Z., Bayard, Q., Franconi, A., Védié, A., Noblet, B., Blanc, J., Amaddeo, G., Ganne‐Carrié, N., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.052 · Cited by 113 · see citing works

Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells

Lin, C.-P., Liu, J., Chow, J., Liu, C.-R., & Liu, H. E. (2006) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3280109424 · Cited by 114 · see citing works

Imetelstat (GRN163L) - Telomerase-Based Cancer Therapy

Röth, A., Harley, C. B., & Baerlocher, G. M. (2009) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-01222-8_16 · Cited by 108 · see citing works

From bench to bedside: the growing use of translational research in cancer medicine.

Goldblatt, E. M., & Lee, W. (2010) · PubMed Central · Cited by 106 · see citing works

A Pharmacological Chaperone Molecule Induces Cancer Cell Death by Restoring Tertiary DNA Structures in Mutant hTERT Promoters

Kang, H.-J., Cui, Y., Yin, H., Scheid, A., Hendricks, W. P. D., Schmidt, J. E., Sekulić, A., Kong, D., Trent, J. M., Gokhale, V. M., et al. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b07598 · Cited by 100 · see citing works

Telomere Maintenance as a Target for Drug Discovery

Sekaran, V. G., Soares, J., & Jarstfer, M. B. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400528t · Cited by 90 · see citing works

Cellular Senescence in the Development and Treatment of Cancer

Saretzki, G. C. (2009) · Current Pharmaceutical Design · doi:10.2174/138161210789941874 · Cited by 88 · see citing works

Telomerase Inhibitor Imetelstat (GRN163L) Limits the Lifespan of Human Pancreatic Cancer Cells

Burchett, K. M., Yan, Y., & Ouellette, M. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085155 · Cited by 84 · see citing works

Targeting telomerase-expressing cancer cells

Ouellette, M. M., Wright, W. E., & Shay, J. W. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01279.x · Cited by 82 · see citing works

The effects of telomerase inhibition on prostate tumor‐initiating cells

Marian, C. O., Wright, W. E., & Shay, J. W. (2010) · International Journal of Cancer · doi:10.1002/ijc.25043 · Cited by 78 · see citing works

DNA modification of live cell surface

Borisenko, G. G., Зайцева, М. А., Chuvilin, A. N., & Pozmogova, G. E. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn1034 · Cited by 75 · see citing works

Therapeutic targeting of replicative immortality

Yaswen, P., MacKenzie, K. L., Keith, W. N., Hentosh, P., Rodier, F., Zhu, J., Firestone, G. L., Matheu, A., Carnero, A., Bilsland, A. E., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.007 · Cited by 74 · see citing works

Antiadhesive Effects of GRN163L—An Oligonucleotide N3′→P5′ <i>Thio</i>-Phosphoramidate Targeting Telomerase

Jackson, S. R., Zhu, C.-H., Paulson, V., Watkins, L., Dikmen, Z. G., Gryaznov, S. M., Wright, W. E., & Shay, J. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2306 · Cited by 72 · see citing works

Specific telomere dysfunction induced by GRN163L increases radiation sensitivity in breast cancer cells

Gómez‐Millán, J., Goldblatt, E. M., Gryaznov, S. M., Mendonca, M. S., & Herbert, B. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.09.038 · Cited by 72 · see citing works

Androgen Receptor Enhances Hepatic Telomerase Reverse Transcriptase Gene Transcription After Hepatitis B Virus Integration or Point Mutation in Promoter Region

Li, C., Li, C., Lin, Y., Ho, M., Chen, D., Chen, P., & Yeh, S. (2018) · Hepatology · doi:10.1002/hep.30201 · Cited by 71 · see citing works

Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells

Wang, X., Hu, C. S., Petersen, B. E., Qiu, J., Ye, F., Houldsworth, J., Eng, K. H., Huang, F., & Hoffman, R. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018022012 · Cited by 68 · see citing works

The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel

Goldblatt, E. M., Gentry, E. R., Fox, M. J., Gryaznov, S. M., Shen, C., & Herbert, B. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1188 · Cited by 66 · see citing works

Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis

Güneş, Ç., Wezel, F., Southgate, J., & Bolenz, C. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0001-5 · Cited by 66 · see citing works

Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors

Sengupta, S., Sobo, M., Lee, K., Kumar, S. S., White, A. R., Mender, I., Fuller, C. E., Chow, L. M. L., Fouladi, M., Shay, J. W., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0792 · Cited by 61 · see citing works

Telomeres and telomerase as targets for cancer therapy

Zimmermann, S., & Martens, U. M. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6481-8 · Cited by 62 · see citing works

Telomeres, senescence, and hematopoietic stem cells

Zimmermann, S., & Martens, U. M. (2007) · Cell and Tissue Research · doi:10.1007/s00441-007-0469-4 · Cited by 64 · see citing works

Targeting telomerase and telomeres to enhance ionizing radiation effects in in vitro and in vivo cancer models

Berardinelli, F., Coluzzi, E., Sgura, A., & Antoccia, A. (2017) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2017.02.004 · Cited by 61 · see citing works

Telomere length and reactive oxygen species levels are positively associated with a high risk of mortality and recurrence in hepatocellular carcinoma

Ko, E., Seo, H., & Jung, G. (2017) · Hepatology · doi:10.1002/hep.29604 · Cited by 60 · see citing works

Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner

Frink, R. E., Peyton, M., Schiller, J. H., Gazdar, A. F., Shay, J. W., & Minna, J. D. (2016) · Oncotarget · doi:10.18632/oncotarget.9335 · Cited by 57 · see citing works

Regulation of Senescence in Cancer and Aging

Kong, Y., Cui, H., Ramkumar, C., & Zhang, H. (2011) · Journal of Aging Research · doi:10.4061/2011/963172 · Cited by 55 · see citing works

Hepatocellular Carcinoma and Other Malignancies in Autoimmune Hepatitis

Czaja, A. J. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2525-5 · Cited by 54 · see citing works

Telomerase as an emerging target to fight cancer — Opportunities and challenges for nanomedicine

Philippi, C., Loretz, B., Schaefer, U. F., & Lehr, C. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.03.025 · Cited by 54 · see citing works

Telomerase-based Cancer Therapeutics: A Review on their Clinical Trials

Relitti, N., Saraswati, A. P., Federico, S., Khan, T., Brindisi, M., Zisterer, D. M., Brogi, S., Gemma, S., Butini, S., & Campiani, G. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200102104930 · Cited by 55 · see citing works

Telomerase inhibitors and ‘T-oligo’ as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity

Rankin, A. M., Faller, D. V., & Spanjaard, R. A. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3282f5d4c2 · Cited by 51 · see citing works

Delivery of Oligonucleotides: Efficiency with Lipid Conjugation and Clinical Outcome

Tran, P., Weldemichael, T., Liu, Z., & Li, H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020342 · Cited by 51 · see citing works

Dissection of Signal Transduction Pathways as a Tool for the Development of Targeted Therapies of Hepatocellular Carcinoma

Calvisi, D. F., Pascale, R. M., & Feo, F. (2007) · Reviews on Recent Clinical Trials · doi:10.2174/157488707781662715 · Cited by 49 · see citing works

Telomere Dysfunction, Chromosomal Instability and Cancer

Meena, J. K., Rudolph, K. L., & Güneş, Ç. (2015) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-20291-4_3 · Cited by 47 · see citing works

Pharmacological intervention strategies for affecting telomerase activity: Future prospects to treat cancer and degenerative disease

Tárkányi, I., & Aradi, J. (2007) · Biochimie · doi:10.1016/j.biochi.2007.09.002 · Cited by 47 · see citing works

Herpesvirus Telomerase RNA (vTR) with a Mutated Template Sequence Abrogates Herpesvirus-Induced Lymphomagenesis

Kaufer, B. B., Arndt, S., Trapp, S., Osterrieder, N., & Jarosinski, K. W. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002333 · Cited by 46 · see citing works

Molecular Mechanisms Underlying Hepatocellular Carcinoma

Merle, P., & TREPO, C. G. (2009) · Viruses · doi:10.3390/v1030852 · Cited by 45 · see citing works

The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells

Koziel, J. E., & Herbert, B. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3270-1 · Cited by 44 · see citing works

Lipid-conjugated telomerase template antagonists sensitize resistant HER2-positive breast cancer cells to trastuzumab

Goldblatt, E. M., Erickson, P. A., Gentry, E. R., Gryaznov, S. M., & Herbert, B. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0201-4 · Cited by 40 · see citing works

Senescence of Tumor Cells in Anticancer Therapy—Beneficial and Detrimental Effects

Piskorz, W. M., & Cechowska‐Pasko, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911082 · Cited by 39 · see citing works

Modulation of telomerase activity in fish muscle by biological and environmental factors

Peterson, D. R., Mok, H. O. L., & Au, D. W. T. (2015) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2015.09.004 · Cited by 38 · see citing works

Development of anticancer drugs based on the hallmarks of tumor cells

Bailón-Moscoso, N., Romero-Benavides, J. C., & Ostrosky‐Wegman, P. (2014) · Tumor Biology · doi:10.1007/s13277-014-1649-y · Cited by 39 · see citing works

Senescence; an endogenous anticancer mechanism.

Vargas, J., Feltes, B. C., Poloni, J. D. F., Lenz, G., & Bonatto, D. (2012) · Frontiers in Bioscience · doi:10.2741/4074 · Cited by 35 · see citing works

Bone Morphogenetic Protein-7 Inhibits Telomerase Activity, Telomere Maintenance, and Cervical Tumor Growth

Cassar, L., Li, H., Pinto, A. R., Nicholls, C., Bayne, S., & Liu, J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1323 · Cited by 36 · see citing works

Functional and mechanistic analysis of telomerase: An antitumor drug target

Chen, Y., & Zhang, Y. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.017 · Cited by 34 · see citing works

Molecular Pathogenesis and Targeted Therapy of Hepatocellular Carcinoma

Zender, L., & Kubicka, S. (2008) · Onkologie · doi:10.1159/000151586 · Cited by 32 · see citing works

Seeding drug discovery: integrating telomerase cancer biology and cellular senescence to uncover new therapeutic opportunities in targeting cancer stem cells

Keith, W. N., Thomson, C. M., Howcroft, J., Maitland, N. J., & Shay, J. W. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.06.009 · Cited by 31 · see citing works

Telomere Dysfunction and DNA Damage Checkpoints in Diseases and Cancer of the Gastrointestinal Tract

Rudolph, K. L., Hartmann, D., & Opitz, O. G. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.07.037 · Cited by 30 · see citing works

Applying small RNA molecules to the directed treatment of human diseases: realizing the potential

Pappas, T. C., Bader, A. G., Andruss, B. F., Brown, D., & Ford, L. P. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.1.115 · Cited by 30 · see citing works

Butylidenephthalide Suppresses Human Telomerase Reverse Transcriptase (TERT) in Human Glioblastomas

Lin, P., Lin, S., Chen, Y.-L., Chang, J., Ho, L.-I., Liu, P.-Y., Chang, L.-F., Harn, Y., Chen, S., Sun, L., et al. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1644-0 · Cited by 29 · see citing works

Epidemiology, risk factors and molecular pathogenesis of primary liver cancer

Hagymási, K., & Tulassay, Z. (2008) · Orvosi Hetilap · doi:10.1556/oh.2008.28313 · Cited by 27 · see citing works

REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY

Lynch, J. P., Metz, D. C., Schuppan, D., Junker, Y., & Barisani, D. (2009) · Cited by 24 · see citing works

MMP-9 silencing regulates hTERT expression via β1 integrin-mediated FAK signaling and induces senescence in glioma xenograft cells

Ponnala, S., Chetty, C., Veeravalli, K. K., Dinh, D. H., Klopfenstein, J. D., & Rao, J. S. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.08.001 · Cited by 22 · see citing works

The Unmasking of Telomerase

Legassie, J. D., & Jarstfer, M. B. (2006) · Structure · doi:10.1016/j.str.2006.09.004 · Cited by 22 · see citing works

Enforced telomere elongation increases the sensitivity of human tumour cells to ionizing radiation

Fairlie, J., & Harrington, L. A. (2014) · DNA repair · doi:10.1016/j.dnarep.2014.11.005 · Cited by 19 · see citing works

Telomerase as a clinical target: Current strategies and potential applications

Fleisig, H. B., & Wong, J. M. Y. (2006) · Experimental Gerontology · doi:10.1016/j.exger.2006.05.011 · Cited by 18 · see citing works

Anticancer Therapy Targeting Telomeres and Telomerase

Parkinson, E. K., & Minty, F. (2007) · BioDrugs · doi:10.2165/00063030-200721060-00005 · Cited by 19 · see citing works

Targeting telomerase with radiolabeled inhibitors

Waghorn, P. A., Jackson, M. R., Gouverneur, V., & Vallis, K. A. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.028 · Cited by 17 · see citing works

Tumor‐Oriented Telomerase‐Terminated Nanoplatform as Versatile Strategy for Multidrug Resistance Reversal in Cancer Treatment

Wu, Y., Zhong, D., Li, Y., Wu, H., Xu, X., Yang, J., & Gu, Z. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.201901739 · Cited by 17 · see citing works

Inhibitors of telomerase and poly(ADP-ribose) polymerases synergize to limit the lifespan of pancreatic cancer cells

Burchett, K. M., Etekpo, A., Batra, S. K., Yan, Y., & Ouellette, M. M. (2017) · Oncotarget · doi:10.18632/oncotarget.19410 · Cited by 16 · see citing works

Therapeutic Targeting of Gastrointestinal Cancer Stem Cells

Stem, J., Flickinger, J. C., Merlino, D. J., Caparosa, E. M., Snook, A. E., & Waldman, S. A. (2019) · Regenerative Medicine · doi:10.2217/rme-2018-0146 · Cited by 16 · see citing works

Telomere-related DNA damage response pathways in cancer therapy: prospective targets

Gu, L., Liu, M., Zhang, Y., Zhou, H., Wang, Y., & Xu, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1379166 · Cited by 16 · see citing works

Chromosomal Number Aberrations and Transformation in Adult Mouse Retinal Stem Cells In Vitro

Djojosubroto, M. W., Bollotte, F., Wirapati, P., Radtke, F., Stamenkovic, I., & Arsenijévic, Y. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-3091 · Cited by 15 · see citing works

Duplex stability of DNA·DNA and DNA·RNA duplexes containing 3′-S-phosphorothiolate linkages

Bentley, J., Brazier, J. A., Fisher, J., & Cosstick, R. (2007) · Organic & Biomolecular Chemistry · doi:10.1039/b713292a · Cited by 14 · see citing works

Stanozolol administration combined with exercise leads to decreased telomerase activity possibly associated with liver aging

Özçağlı, E., Kara, M., Kotil, T., Fragkiadaki, P., Tzatzarakis, M. N., Tsitsimpikou, C., Stivaktakis, P. D., Tsoukalas, D., Spandidos, D. A., Tsatsakis, A. M., et al. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3644 · Cited by 14 · see citing works

Telomerase and the endocrine system

Pacini, F., Cantara, S., Capezzone, M., & Marchisotta, S. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.52 · Cited by 14 · see citing works

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling

Olschok, K., Altenburg, B., Toledo, M. A. S., Maurer, A., Abels, A., Beier, F., Gezer, D., Isfort, S., Paeschke, K., Brümmendorf, T. H., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1277453 · Cited by 13 · see citing works

Geographic and Viral Etiology Patterns of TERT Promoter and CTNNB1 Exon 3 Mutations in Hepatocellular Carcinoma: A Comprehensive Review

Terra, M. L., Sant’Anna, T. B. F., de Barros, J. J. F., & Araujo, N. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26072889 · Cited by 13 · see citing works

Mechanism of interaction of small transcription inhibitors with DNA in the context of chromatin and telomere

Ghosh, S., Majumder, P., Pradhan, S. K., & Dasgupta, D. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.06.008 · Cited by 12 · see citing works

TPP1 OB-fold domain protein suppresses cell proliferation and induces cell apoptosis by inhibiting telomerase recruitment to telomeres in human lung cancer cells

Zhu, J., Liu, W., Chen, C., Zhang, H., Yue, D., Li, C., Zhang, L., Gao, L., Huo, Y., Liu, C., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02921-3 · Cited by 12 · see citing works

Improvement in the Current Therapies for Hepatocellular Carcinoma Using a Systems Medicine Approach

Özcan, M., Altay, Ö., Lam, S. C. C., Türkez, H., Aksoy, Y., Nielsen, J., Uhlén, M., Borén, J., & Mardinoğlu, A. (2020) · Advanced Biosystems · doi:10.1002/adbi.202000030 · Cited by 12 · see citing works

Short-term treatment with imetelstat sensitizes hematopoietic malignant cells to a genotoxic agent via suppression of the telomerase-mediated DNA repair process

Hidaka, D., Onozawa, M., Miyashita, N., Yokoyama, S., Nakagawa, M., Hashimoto, D., & Teshima, T. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1779256 · Cited by 10 · see citing works

Cellular Senescence and Tumor Suppression

Adams, P. D., & Sedivy, J. M. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1075-2 · Cited by 10 · see citing works

Telomerase: a good target in hepatocellular carcinoma? An overview of relevant preclinical data

Tornesello, M., Tornesello, A., Starita, N., Cerasuolo, A., Izzo, F., Buonaguro, L., & Buonaguro, F. (2022) · Expert opinion on therapeutic targets · doi:10.1080/14728222.2022.2147062 · Cited by 9 · see citing works

The inhibitory effect of helenalin on telomerase activity is attributed to the alkylation of the CYS445 residue: Evidence from QM/MM simulations

Zhang, Z., Xu, L., & Cheung, H. (2014) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2014.04.012 · Cited by 9 · see citing works

Regulation of telomerase towards tumor therapy

Yan, S., Song, L., Qiu, H., Wang, X., He, Y., Wang, C., & Huang, Y. Y. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01181-6 · Cited by 9 · see citing works

Telomerase as a Target for Cancer Therapeutics

Shay, J. W. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6102-0_13 · Cited by 8 · see citing works

The promise of telomere length, telomerase activity and its regulation in the translocation-dependent cancer ESFT; clinical challenges and utility

Proctor, A., Brownhill, S. C., & Burchill, S. A. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.02.011 · Cited by 8 · see citing works

Telomerase activity: An attractive target for cancer therapeutics

Picariello, L. (2014) · World Journal of Pharmacology · doi:10.5497/wjp.v3.i4.86 · Cited by 8 · see citing works

243 GRN163 and GRN163L, telomerase template antagonists, inhibit the growth of human hepatoma in vivo

Djojosubroto, M. W., Chin, A. C., Go, N. F., Wunder, E., Karpf, D. B., & Rudolph, K. L. (2004) · Journal of Hepatology · doi:10.1016/s0168-8278(04)90243-7

Preclinical development of GRN163L, a telomerase inhibitor for cancer therapy

Tressler, R., Chin, A. C., Gryaznov, S. M., & Harley, C. B. (2005) · Cancer Research

Preclinical efficacy, safety, and ADME of GRN163L, a novel telomerase inhibitor developed for the treatment of cancer

Tressler, R. J., Chin, A., Gryaznov, S. M., & Harley, C. B. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3168 · Cited by 2 · see citing works

A novel telomerase template antagonist (GRN163) as a potential anticancer agent.

Asai, A., Oshima, Y., Yamamoto, Y., Uochi, T., Kusaka, H., Akinaga, S., Yamashita, Y., Pongracz, K., Pruzan, R., Wunder, E., et al. (2003) · PubMed · Cited by 239 · see citing works

Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer

Gellert, G. C., Dikmen, Z. G., Wright, W. E., Gryaznov, S. M., & Shay, J. W. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9043-5 · Cited by 126 · see citing works